Neumora Therapeutics, Inc. Common Stock Q4 FY2024 earnings call

• New leadership: Paul Berns as CEO and Josh Pinto as President. • Pipeline updates: Navacaprant in Phase 3 for MDD with changes to KOASTAL studies based on KOASTAL-1 learnings; NMRA-511 in Phase 1b for Alzheimer's disease agitation; M4 franchise to progress next compound into clinic by mid-2025; four preclinical programs advancing. • Financial position: Strong with $307.6M in cash, cash equivalents, and marketable securities, supporting operations into mid-2026. • Operational changes: For navacaprant, enhancing medical monitoring with SAFER, using Verified Clinical Trial screening database, and selecting experienced sites for KOASTAL-2 and 3.

No specific product segment financial performance detailed in the transcript

• Expect to report top line data from KOASTAL-3 in Q1 2026 and KOASTAL-2 in Q2 2026. • Cash runway supports operations into mid-2026. • Plan to progress M4 franchise compound into clinic by mid-2025.

• Uncertainties in clinical trial outcomes, such as potential differences in study results from KOASTAL-1. • Risks associated with drug development and potential failures in meeting study endpoints.

Q: Elaborate on differences between vendor for KOASTAL-1 and SAFER, and changes in site auditing and patient caps for KOASTAL-2 and 3 A: Bill Aurora and Josh Pinto discussed enhancing medical monitoring with SAFER, a review by MGH psychiatrists, using Verified Clinical Trial screening database, and selecting experienced sites for KOASTAL-2 and 3 Q: Perspective on enrollment progress in KOASTAL-2 and 3, impact of changes, and gender differences in KOASTAL-1 A: Josh Pinto and Bill Aurora talked about site experience impact, placebo response, and added measures to optimize patient population for KOASTAL-2 and 3 Q: Retrospective on KOASTAL-1, MADRS score, site granularity, and patient per site in KOASTAL-2 and 3 A: Josh Pinto and Bill Aurora addressed baseline scores, site removal, and that KOASTAL-2 and 3 are sized similarly with flexibility to increase sample size Q: PK data from KOASTAL-1, site performance, sex-based differences, and enrollment increase for KOASTAL-2 and 3 A: Bill Aurora discussed PK data consistency with Phase 2, and Josh Pinto mentioned flexibility in sample size increase for KOASTAL studies Q: Powering assumptions for KOASTAL studies and interim analysis for KOASTAL-2 and 3 A: Bill Aurora stated no modification to powering assumptions, and Josh Pinto mentioned no interim analysis planned yet Q: NMRA-266 clinical hold update and convulsions A: Josh Pinto discussed working to move NMRA-266 off clinical hold and progress on M4 franchise compounds